CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 生产领域的新参与者：脐带血与外周血策略的比较
英文原题：New player in CAR-T manufacture field: comparison of umbilical cord to peripheral blood strategies.
查看英文原题
New player in CAR-T manufacture field: comparison of umbilical cord to peripheral blood strategies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T（CAR-T）细胞疗法通常采用患者自体外周血T细胞制备，但制备周期、患者细胞质量和成本等因素限制了治疗的可及性。异体供者血液和脐带血（UCB）提供了替代细胞来源；脐带血库可能支持现成型产品的开发。本综述比较自体与异体血液来源以及脐带血来源的CAR-T 细胞制备策略，并讨论各自的优势、局限和临床转化问题。
展开英文摘要原文
One of the most successful treatments in hematologic cancer is chimeric antigen receptor (CAR)-T cell-based immunotherapy.
However, CAR-T therapy is not without challenges like the costly manufacturing process required to personalize each treatment for individual patients or graft-versus-host disease. Umbilical cord blood (UCB) has been most commonly used for hematopoietic cell transplant as it offers several advantages, including its rich source of hematopoietic stem cells, lower risk of graft-versus-host disease, and easier matching for recipients due to less stringent HLA requirements compared to bone marrow or peripheral blood stem cells.
In this review, we have discussed the advantages and disadvantages of different CAR-T cell manufacturing strategies with the use of allogeneic and autologous peripheral blood cells.
We compare them to the UCB approach and discuss ongoing pre-clinical and clinical trials in the field.
Finally, we propose a cord blood bank as a readily available source of CAR-T cells.
论文信息
- 作者
- Rassek K、Misiak J、Ołdak T、Rozwadowska N、Basak G、Kolanowski T
- 单位
- Institute of Human Genetics, Polish Academy of Sciences, Poznan, Poland.Poland
- 文献类型
- 综述 · 对照研究
- 期刊
- Frontiers in immunology2025
- 原文标识
- PubMed 40191201 · DOI 10.3389/fimmu.2025.1561174
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →